 |
|
|
|
 |
|
|
| Article 1 to 10 out of 18 concerning CuraGen Corporation
|
-
Roche acquires 454 Life Sciences to strengthen presence in ultra-fast gene sequencing
(02 Apr 2007)
Roche and CuraGen announced that they have signed a definitive agreement under which Roche will acquire 100% of 454 Life Sciences, a majority-owned subsidiary of CuraGen Corporation, active in high-throughput DNA sequencing. Under the terms of the ...
-
TopoTarget and CuraGen Initiate Phase II Trial of Belinostat (PXD101) in Combination with Velcade
(30 Mar 2007)
TopoTarget A/S and CuraGen Corporation announced the initiation of patient dosing in a Phase II open-label, multi-center clinical trial evaluating the efficacy and safety of intravenous belinostat (PXD101), a small molecule histone deacetylase ...
-
TopoTarget and CuraGen Initiate NCI-Sponsored Phase II Trial of PXD101 for Ovarian Cancer
(16 Nov 2006)
TopoTarget A/S and CuraGen Corporation announced the initiation of patient dosing in a Phase II clinical trial evaluating the antitumor activity of intravenous PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of ...
-
Southwest Oncology Group Opens New Lymphoma Trial with CuraGen's and TopoTarget's PXD101
(28 Aug 2006)
CuraGen Corporation and TopoTarget A/S announced the Southwest Oncology Group, a national clinical trials cooperative group, has just opened a Phase II clinical trial to test the effects of a new investigational agent on aggressive B-cell lymphoma. ...
-
CuraGen and TopoTarget Initiate Clinical Program Evaluating Oral Administration of PXD101
(14 Aug 2006)
Phase I trial to establish the dose and frequency for oral PXD101 in patients with advanced solid tumors
CuraGen Corporation and TopoTarget A/S announced the initiation of a Phase I clinical trial evaluating the administration of oral PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in patients with advanced solid tumors. The Phase I ...
-
CuraGen and TopoTarget Initiate NCI-sponsored Phase I Clinical Trial of PXD101 and Azacitidine
(10 Aug 2006)
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase I clinical trial evaluating the safety and tolerability of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with azacitidine ...
-
CuraGen: Changes to Metabolic Disease Collaboration for the Development of BAY 76-7171
(21 Jul 2006)
CuraGen Corporation has been informed by Bayer Pharmaceuticals Corporation that Bayer plans to license BAY 76-7171 (formerly CT052). BAY 76-7171 was discovered under an ongoing metabolic disorder collaboration between CuraGen and Bayer aimed at ...
-
CuraGen and TopoTarget Initiate Phase Ib/II Clinical Trial with PXD101 and Velcade(R) for Multiple Myeloma
(24 Mar 2006)
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase Ib/II proof-of-concept trial to evaluate PXD101, a small molecule histone deacetylase (HDAC) inhibitor, in combination with Velcade(R) (bortezomib) for the ...
-
CuraGen and TopoTarget Initiate Phase II Clinical Trial for treatment of T-Cell Lymphoma
(06 Feb 2006)
CuraGen Corporation and TopoTarget A/S announced the initiation of patient dosing in a Phase II clinical trial evaluating the efficacy and safety of PXD101, a small molecule histone deacetylase (HDAC) inhibitor, for the treatment of cutaneous T-cell ...
-
454 Life Sciences and the Genome Sequencing Center at Washington University in St. Louis Announce Collaborative Research Plan
(09 Dec 2005)
454 Life Sciences Corporation, a majority-owned subsidiary of CuraGen Corporation , and the Genome Sequencing Center (GSC) at Washington University School of Medicine in St. Louis announced a collaborative research plan to sequence disease-causing ...
|
|
|
|
|
Top
